To include your compound in the COVID-19 Resource Center, submit it here.

Xtandi meets in Phase III for non-metastatic CRPC

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (Tokyo:4503) said Xtandi enzalutamide plus androgen deprivation therapy met the primary endpoint of improving metastasis-free

Read the full 227 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE